Rapamycin abrogates accelerated rejection in sensitized rats by selectively suppressing intragraft cell activation, adhesion/binding properties, and modulating serum alloantibody responses.
Schmidbauer
G
G
Department of Surgery, Justus Liebig University, Giessen, Germany.
Hancock
W W
WW
Wasowska
B
B
Binder
J
J
Padberg
W
W
Kupiec-Weglinski
J W
JW
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control*; D016027:Heart Transplantation / Q000276:immunology*; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016219:Immunotherapy, Adoptive; D007518:Isoantibodies / Q000097:blood*; D008198:Lymph Nodes / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D011090:Polyenes / Q000627:therapeutic use*; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D020123:Sirolimus; D016038:Skin Transplantation / Q000276:immunology*; D014185:Transplantation, Isogeneic
D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011090:Polyenes; D020123:Sirolimus